🇺🇸

US SEC Filing Intelligence

· daily

HHS & Healthcare Contracts Intelligence — May 20, 2026

Over a single day, May 20, 2026, the Department of Health and Human Services (HHS) awarded two defense-related contracts totaling $134.8 million, both under BARDA for medical countermeasure R&D. The dominant theme is biodefense and antimicrobial resistance (AMR) preparedness, with Venatorx Pharmaceuticals receiving a $72.1M cost-plus-fixed-fee contract (potential $318.6M) for an AMR antibiotic, and SELUX Diagnostics receiving a $62.6M contract (potential $70.6M) for biotechnology R&D. The highest-conviction signal is Venatorx’s long-duration (through 2032) contract tied to a priority national security area, but both awards carry neutral signals due to cost-plus pricing limiting upside and SELUX’s contract ending May 2025, creating near-term revenue cliff risk. Key watch items include option exercises for Venatorx and SELUX’s ability to secure follow-on awards.

2 total filings
· daily

New Federal Contractors — May 20, 2026

This digest of 11 new federal contracts, totaling $1.87 billion, reveals a civilian-agency-dominated landscape (9 of 11 contracts) with NASA as the standout spender, accounting for $1.08 billion (58%) of total obligations. The highest-conviction signal is Northrop Grumman's $569.5 million firm-fixed-price delivery order for the JPSS-2 spacecraft, a long-duration (13-year) NASA/NOAA polar satellite program that reinforces its competitive moat in large space systems. Key risks include execution pressure on fixed-price contracts for complex space vehicles and the absence of defense-related awards from the DoD, which limits near-term defense sector exposure. Investors should watch NASA's budget trajectory for Earth science and space R&D, as well as option exercises on the RTX and Venatorx contracts.

11 total filings
· daily

Significant Contract Modifications ($10M+) — May 20, 2026

This digest of 11 government contracts, totaling $1.87 billion in obligations from a single day (May 20, 2026), reveals a pronounced civilian-agency tilt, with only 2 of 11 contracts defense-related. NASA dominates the period, accounting for $1.085 billion (58%) of total value, driven by a $569.5 million Northrop Grumman JPSS-2 spacecraft delivery order and a $445 million Caltech/JPL R&D award. The highest-conviction signal is the Northrop Grumman contract, a long-duration, fixed-price win that reinforces its competitive moat in large space systems but carries execution risk. A key watch item is the heavy concentration in NASA and HHS (combined $1.36 billion, 73% of total), which exposes investors to civilian budget risk, particularly under a potential Continuing Resolution (CR) scenario that could delay new obligations. No bearish signals were identified, but neutral signals on nine contracts highlight limited near-term margin catalysts and execution risks on fixed-price awards.

11 total filings
· daily

Contract Deobligations Alert — May 20, 2026

This digest of 11 contracts, totaling $1.87 billion in obligations, reveals a heavily civilian-skewed procurement landscape (9 of 11 contracts) led by NASA and HHS, with defense-related awards comprising only 2 contracts. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price NASA award for the JPSS-2 spacecraft, a long-duration, high-materiality win that reinforces its competitive moat in space systems. A key risk is the lack of any DOD contracts in the set, suggesting a potential pause or CR-related slowdown in defense procurement during this period, while civilian agency spending—particularly NASA space R&D and HHS health security—remains robust. Investors should watch for execution risk on Northrop Grumman's fixed-price space vehicle contract and monitor NASA budget allocations for Earth science programs that underpin RTX's $200M Landis instrument award.

11 total filings
· daily

Contract Option Exercises — May 20, 2026

This digest covers 11 contract option exercises totaling $1.87B, with only 2 defense-related awards (18%) and the remainder civilian, primarily NASA and HHS. The dominant theme is NASA's sustained investment in space R&D and Earth science, led by a $569.5M Northrop Grumman JPSS-2 spacecraft award—the highest-conviction bullish signal. The aggregate signal strength is moderate (5.2/10), reflecting a mix of large, stable NASA contracts and smaller civilian IT and health awards with limited direct equity exposure. Key risk: the heavy civilian tilt (9 of 11 contracts) exposes investors to potential budget scrutiny under a Continuing Resolution, while the absence of DOD contracts limits defense sector upside.

11 total filings
· daily

Federal Professional Services Contracts — May 20, 2026

This digest covers a single $151.7M civilian agency contract awarded to Magellan Federal (Centene subsidiary) by the Department of the Interior, with no defense exposure. The contract provides personal financial counselors on a time-and-materials basis, signaling stable but margin-capped recurring revenue. The highest-conviction signal is the neutral-to-bearish pricing structure (T&M) and high subaward pass-through ($45.9M), which limits margin expansion and competitive moat. Key risks include budget scrutiny for non-core civilian support functions and potential option year non-exercise.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — May 20, 2026

The two civilian Health and Human Services contracts awarded to Deloitte & Touche LLP and SOFTRAMS LLC total $138.1 million in obligations, with zero defense exposure. The dominant theme is sustained federal IT modernization, specifically at NIH’s National Cancer Institute and CMS, where demand for digital services and application development remains robust. The highest-conviction signal is Deloitte’s $69.7 million obligated contract, which provides near-term revenue visibility for the privately held firm, though its lack of public equity limits direct investment applicability. A key risk is SOFTRAMS LLC’s fixed-price execution burden, which could compress margins for this small HUBZone business if costs overrun. Overall, the digest signals stable civilian IT spending but offers limited actionable equity opportunities due to the private status of both recipients.

2 total filings
· daily

NASA & Space Contracts Intelligence — May 20, 2026

This digest covers $1.28B in NASA-only contracts awarded to three entities—Northrop Grumman, Caltech (JPL), and RTX Corp (Raytheon)—with zero defense-related obligations, underscoring a pure civilian space and science procurement theme. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a 13-year program that adds a large, durable revenue stream to its space systems segment but carries execution risk on a complex polar satellite mission. A key risk is the fixed-price structure on Northrop Grumman's contract, which could compress margins if cost overruns occur, while the two Caltech awards ($515M combined) offer no direct equity upside due to their cost-only or cost-plus-fee structures. The aggregate data reveals a stable, long-duration NASA investment cycle in polar weather satellites and early-stage space R&D, with no near-term re-compete pressure on the largest awards.

4 total filings
· daily

All HHS Contracts — May 20, 2026

Over a single-day period (May 20, 2026), HHS awarded $272.9M in obligations across four contracts, with 2 of 4 defense-related (BARDA) totaling $134.8M, signaling sustained biodefense and health security prioritization. The dominant theme is HHS/BARDA investment in antimicrobial resistance (AMR) and medical countermeasures, led by a $72.1M Venatorx Pharmaceuticals award with a $318.6M ceiling through 2032. The highest-conviction signal is Venatorx's cost-plus-fixed-fee structure and long performance period, providing low-risk, durable revenue in a high-priority national security area. Key risk: SELUX Diagnostics' contract ends May 2025, limiting future upside and creating a potential revenue cliff for that small business.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — May 20, 2026

This digest covers $1.366 billion in civilian-only mega contracts (0/4 defense-related) awarded on a single day, May 20, 2026, with an average signal strength of 6.0/10. NASA dominates the period, accounting for $1.215 billion (89%) of total obligations across three awards to Northrop Grumman, Caltech/JPL, and RTX Corp (Raytheon). The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a 13-year program with 8/10 bullish strength. Key risk: the fixed-price structure on a complex space vehicle introduces execution risk, while the civilian-only mix means no direct defense budget tailwind from NDAA priorities. The Department of Interior's $151.7M award to Centene's Magellan Federal for personal financial counselors is a neutral, non-core support contract with limited margin upside due to T&M pricing.

4 total filings
· daily

High-Value Federal Grants ($5M+) — May 20, 2026

This digest of 11 high-value federal grants, totaling $1.87 billion, reveals a pronounced civilian agency tilt, with only 2 of 11 contracts defense-related. NASA dominates the award landscape, accounting for over $1.28 billion across four contracts, including a $569.5 million firm-fixed-price delivery order to Northrop Grumman for the JPSS-2 spacecraft—the highest-conviction bullish signal. The strongest cross-contract pattern is NASA's sustained investment in space R&D and satellite programs, which benefits primes like Northrop Grumman and RTX Corp. However, the neutral average signal strength (5.2/10) and the absence of any bearish signals mask execution risk on fixed-price contracts and budget uncertainty under a potential Continuing Resolution. Key watch items include Northrop Grumman's JPSS-2 delivery milestones and the exercise of options on RTX's $200 million Landis flight instrument contract.

11 total filings
· daily

All NASA Contracts — May 20, 2026

This digest covers $1.28 billion in NASA obligations from May 20, 2026, with zero defense-related awards, underscoring a pure civilian space and science R&D theme. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a long-duration (13-year) program that adds substantial backlog to its space systems segment but carries execution risk on a complex polar satellite mission. A key risk is the $445M Caltech sole-source award for JPL management, which concentrates NASA's early-stage R&D spending with a non-profit entity offering no direct public equity exposure. Investors should watch for JPSS-2 delivery milestones and NASA's Earth science budget allocations for the $200M Raytheon Landis instrument contract.

4 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 20, 2026

The S&P 500 Technology sector is rapidly bifurcating between AI-driven hyper-growth and terrestrial restructuring. Leading the charge, **NVIDIA** delivered an extraordinary +85% YoY revenue surge to $81.6B, while **Analog Devices** rode the industrial rebound to +37% YoY growth, their highest in recent history. However, this momentum is juxtaposed against significant operational tightening: **Intuit** announced a 17% workforce reduction and up to $340M in charges, and **Aditxt** faces a liquidity crisis with cash dwindling to $269K and a ballooning $35M stockholder deficit. Capital allocation is mixed; NVIDIA raised its dividend 25x (to $0.25) and added $80B in buyback authority, while Salesforce aggressively repurchased 103M shares, distorting governance metrics. The AI infrastructure buildout is the dominant theme—NVIDIA's Data Center revenue hit $75.2B (+92% YoY)—but supply chain buildup (NVIDIA inventories +20% QoQ to $25.8B) and China revenue exclusion in guidance present notable risks. Insider activity was sparse in this batch, reducing conviction signals, but compensation-related shareholder dissent at **Iridium** (13.2% against say-on-pay) flags governance tension.

9 high priority 12 medium 21 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 20, 2026

The May 20, 2026 batch of 23 NASDAQ-100 filings reveals a sharply bifurcated market: mega-cap semiconductor leaders NVIDIA and Analog Devices post explosive growth (85% and 37% YoY revenue gains), while micro-cap clinical-stage and pre-revenue companies (Immunovant, Aditxt, Loan AI, Mosaic) show accelerating cash burns, widening losses, and deteriorating balance sheets. Period-over-period comparisons confirm an AI-driven investment cycle is compressing margins at scale—NVIDIA's R&D spend surged 58.5% YoY, Intuit's R&D rose 18.8%—despite strong top-line growth. Capital allocation trends diverge sharply: NVIDIA announced an $80B buyback and 25x dividend hike, and Starbucks retired $1.32B in debt, contrasting with cash-strapped biotechs drawing on dilutive equity offerings (Immunovant raised $544M). Insider activity shows no direct selling signals in this batch, but shareholder dissent at Iridium (13.2% against say-on-pay) and ADI's $29M severance program hint at governance and restructuring risks. The portfolio-level takeaway is a 'growth-at-a-cost' regime favoring dominant AI beneficiaries, while speculative names face a liquidity crunch.

10 high priority 13 medium 23 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 20, 2026

The 50 filings from the S&P 500 Financials sector and related companies reveal a bifurcated landscape: traditional financial institutions face margin compression and rising credit losses, while asset managers and fintech innovators push into digital assets and alternative structures. Key period-over-period trends show revenue growth in select industrial and tech-adjacent financials (Analog Devices +37% YoY, CAVA +32.1%), but net income declines dominate the banking and REIT subsectors (Sachem Capital swung to -$6.1M net loss, PrimeEnergy -52.5% net income). The most critical developments include Morgan Stanley's dual crypto trust filings (Solana and Ethereum), signaling institutional crypto adoption acceleration, and the $2.25B Moderna settlement by Roivant Sciences, which creates a massive cash position for biotech deployment. Portfolio-level patterns reveal aggressive capital allocation toward share repurchases (News Corp $1B program, Salesforce $25B ASR) versus organic reinvestment, while insider activity remains muted across the sample, with no major CEO purchases or sales detected. The data suggests investors should favor asset-light, growth-oriented financial platforms over traditional lenders facing credit cycle headwinds.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 20, 2026

The 50 filings for S&P 500 Consumer Staples on May 20, 2026, reveal a sector in transition, with a strong undercurrent of financial engineering and capital market activity, but limited direct operational data from core staples companies. Key themes include significant debt offerings and refinancings (Eli Lilly, Travel + Leisure, Wells Fargo), leadership transitions (Choice Hotels, Philip Morris), and a major M&A deal (Envirotech Vehicles/Azio AI). Period-over-period data from the limited set of consumer-related companies shows a mixed picture: Haemonetics reported a 2% revenue decline and a 42% net income drop, while CorVel showed 7% revenue growth and 17% EPS growth. The most actionable insights come from capital allocation moves, such as Eli Lilly's $8.94B debt raise to fund a pending acquisition and Travel + Leisure's $900M refinancing, signaling strategic shifts. Insider activity is sparse, but the significant shareholder dissent at Verra Mobility (33% withheld votes) and the 40% opposition to Castellum's stock plan are notable governance risk flags. The overall sentiment is neutral to mixed, with opportunities in companies executing well (CorVel) and risks in those with deteriorating fundamentals (Haemonetics, KonaTel).

25 high priority 25 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 20, 2026

The 50 filings for S&P 500 Industrials on May 20, 2026, reveal a bifurcated landscape: strong cyclical recovery in semiconductors (Analog Devices revenue +37% YoY) contrasts with acute distress in small-cap industrials (Treasure Global net loss swing of -$3.58M YoY, Ionetix pre-revenue cash burn). The dominant themes are leadership transitions (Choice Hotels, Diamondback Energy, Schrodinger) and capital market activity (S&P Global $2B spin-off debt, Deep Fission $150M IPO, GEN Restaurant $50M shelf). Cybersecurity risk is elevated (West Pharmaceutical attack with data exfiltration). Insider activity is notably absent across filings, but capital allocation signals are mixed: dividend increases (TrustCo $0.38/sh) vs. dilutive offerings (NanoViricides $2M, WidePoint $5M). The sector shows a clear divergence between large-cap industrial strength and micro-cap fragility, with M&A integration (Santander/Webster) and IPOs providing catalyst opportunities.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 20, 2026

The four filings in the S&P 500 Energy sector for May 20, 2026, reveal a mix of routine governance and financial distress. COPT Defense Properties and Mid-America Apartments (MAA) held annual meetings with strong shareholder support, though MAA's director Tamara Fischer faced notable opposition (91.1% for). Halliburton's meeting also passed all proposals, but director T.M. Edwards Young received significant opposition (92.1M votes against). Copley Acquisition Corp reported a net income turnaround to $1.29M from a loss of $74,699 YoY, driven by trust dividends, but cash plummeted 94% to $4,235 and expenses surged 255%. No period-over-period comparisons for revenue or margins exist as these are non-operational entities. No insider trading activity was reported. Forward-looking data is absent except for Copley's ongoing working capital loan. Capital allocation is limited to dividend income for Copley. The key theme is the divergence between stable, well-governed REITs and a cash-burning SPAC with no operating revenue.

1 high priority 3 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — May 20, 2026

The May 20, 2026, filings reveal a market dominated by strategic capital management and leadership transitions, with a notable undercurrent of financial distress in smaller-cap companies. The most significant capital market activity includes a massive $3.75 billion revolving credit facility for Williams Companies and a $1.375 billion bond issuance for Appalachian Power, signaling robust access to credit for large-cap infrastructure. However, a contrasting theme of financial strain is evident in filings from Golden Minerals, GridAI, and NanoViricides, which are resorting to dilutive equity offerings or debt settlements to manage liquidity. Leadership changes are widespread, with notable CEO departures at Choice Hotels and Clean Harbors, and CFO transitions at Philip Morris, Skillz, and Stryker, suggesting a period of corporate recalibration. While most governance filings (annual meeting results) were routine, the aggregate data points to a bifurcated market where large, well-capitalized firms are optimizing their balance sheets, while smaller entities face existential funding challenges. The overall sentiment is mixed, with a tilt toward cautious optimism in the energy and infrastructure sectors, contrasted by heightened risk in small-cap biotech and mining.

50 high priority 50 total filings